CoChat

Lipids in Atherosclerosis: Pathophysiology and the Role of Calculated Lipid Indices in Assessing Cardiovascular Risk in Patients with Hyperlipidemia

Gaggini, Melania, Gorini, Francesca, Vassalle, Cristina · 2022 · International Journal of Molecular Sciences
Cited by 163

The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.

Abstract

The role of lipids is essential in any phase of the atherosclerotic process, which is considered a chronic lipid-related and inflammatory condition. The traditional lipid profile (including the evaluation of total cholesterol, triglycerides, high-density lipoprotein, and low-density lipoprotein) is a well-established tool to assess the risk of atherosclerosis and as such has been widely used as a pillar of cardiovascular disease prevention and as a target of pharmacological treatments in clinical practice over the last decades. However, other non-traditional lipids have emerged as possible alternative predictors of cardiometabolic risk in addition to traditional single or panel lipids, as they better reflect the overall interaction between lipid/lipoprotein fractions. Therefore, this review deals with the lipid involvement characterizing the pathophysiology of atherosclerosis, discussing some recently proposed non-traditional lipid indices and, in the light of available knowledge, their actual potential as new additive tools to better stratify cardiovascular risk in patients with hyperlipidemia as well as possible therapeutic targets in the clinical practice.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/ijms24010075

Cites

28 of 28 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 93

  1. Ralapanawa, 2021, Epidemiology and the Magnitude of Coronary Artery Disease and Acute Coronary Syndrome: A Narrative Review, J. Epidemiol. Glob. Health, 11, 169, 10.2991/jegh.k.201217.001 · DOI · Paper page
  2. Wilson, 2022, The intracellular signaling pathways governing macrophage activation and function in human atherosclerosis, Biochem. Soc. Trans, 50, 1673, 10.1042/BST20220441 · DOI
  3. Jakubiak, G.K., Pawlas, N., Cieślar, G., and Stanek, A. (2021). Pathogenesis and Clinical Significance of In-Stent Restenosis in Patients with Diabetes. Int. J. Environ. Res. Public Health, 18. · DOI
  4. Poder, T.G., Erraji, J., Coulibaly, L.P., and Koffi, K. (2017). Percutaneous coronary intervention with second-generation drug-eluting stent versus bare-metal stent: Systematic review and cost-benefit analysis. PLoS ONE, 12. · DOI
  5. Minelli, 2020, Reflections on Atherosclerosis: Lesson from the Past and Future Research Directions, J. Multidiscip. Healthc., 13, 621, 10.2147/JMDH.S254016 · DOI
  6. Ross, 1999, Atherosclerosis—An Inflammatory Disease, N. Engl. J. Med., 340, 115, 10.1056/NEJM199901143400207 · DOI · Paper page
  7. Li, 2022, Recent Advance in Treatment of Atherosclerosis: Key Targets and Plaque-Positioned Delivery Strategies, J. Tissue Eng., 13, 20417314221088508, 10.1177/20417314221088509 · DOI
  8. Pirillo, 2018, The Interplay of Lipids, Lipoproteins, and Immunity in Atherosclerosis, Curr. Atheroscler. Rep., 20, 1, 10.1007/s11883-018-0715-0 · DOI
  9. Barzi, 2005, A comparison of lipid variables as predictors of cardiovascular disease in the Asia Pacific region, Ann. Epidemiol., 15, 405, 10.1016/j.annepidem.2005.01.005 · DOI
  10. Malekmohammad, K., Sewell, R.D., and Rafieian-Kopaei, M. (2019). Antioxidants and Atherosclerosis: Mechanistic Aspects. Biomolecules, 9. · DOI · Paper page
  11. Sies, 2005, Nutritional, Dietary and Postprandial Oxidative Stress, J. Nutr., 135, 969, 10.1093/jn/135.5.969 · DOI · Paper page
  12. Venugopal, S.K., Anoruo, M., and Jialal, I. (2022, December 15). Biochemistry, Low Density Lipoprotein. Available online: https://europepmc.org/article/NBK/nbk500010.
  13. Gleissner, 2007, Effects of Native and Modified Low-Density Lipoproteins on Monocyte Recruitment in Atherosclerosis, Hypertension, 50, 276, 10.1161/HYPERTENSIONAHA.107.089854 · DOI
  14. Formoso, 2016, Physiology and Pathophysiology of OxLDL Uptake by Vascular Wall Cells in Atherosclerosis, Vascul. Pharmacol., 84, 1, 10.1016/j.vph.2016.05.013 · DOI · Paper page
  15. Zakiev, 2016, Lipid Composition of Circulating Multiple-Modified Low Density Lipoprotein, Lipids Health Dis., 15, 1, 10.1186/s12944-016-0308-2 · DOI · Paper page
  16. Orekhov, 2017, Circulating Desialylated Low Density Lipoprotein, Cor. Vasa., 59, e149, 10.1016/j.crvasa.2016.10.003 · DOI
  17. Poznyak, A.V., Wu, W.-K., Melnichenko, A.A., Wetzker, R., Sukhorukov, V., Markin, A.M., Khotina, V.A., and Orekhov, A.N. (2020). Signaling Pathways and Key Genes Involved in Regulation of Foam Cell Formation in Atherosclerosis. Cells, 9. · DOI
  18. Malekmohammad, 2021, Role of Lipid Accumulation and Inflammation in Atherosclerosis: Focus on Molecular and Cellular Mechanisms, Front. Cardiovasc. Med., 8, 707529, 10.3389/fcvm.2021.707529 · DOI · Paper page
  19. Villegas, 2012, Electronegative Low-Density Lipoprotein. A Link between Apolipoprotein B Misfolding, Lipoprotein Aggregation and Proteoglycan Binding, Curr. Opin. Lipidol., 23, 479, 10.1097/MOL.0b013e328357c933 · DOI
  20. Maiolino, 2013, The Role of Oxidized Low-Density Lipoproteins in Atherosclerosis: The Myths and the Facts, Mediat. Inflamm., 2013, 714653, 10.1155/2013/714653 · DOI · Paper page
  21. Summerhill, V.I., Grechko, A.V., Yet, S.-F., Sobenin, I.A., and Orekhov, A.N. (2019). The Atherogenic Role of Circulating Modified Lipids in Atherosclerosis. Int. J. Mol. Sci., 20. · DOI · Paper page
  22. Mofidi, 2001, Association between Plaque Instability, Angiogenesis and Symptomatic Carotid Occlusive Disease, J. Br. Surg., 88, 945, 10.1046/j.0007-1323.2001.01823.x · DOI · Paper page
  23. Hansson, 2006, Inflammation and Atherosclerosis, Annu. Rev. Pathol. Mech. Dis., 1, 297, 10.1146/annurev.pathol.1.110304.100100 · DOI · Paper page
  24. Abdolmaleki, 2019, Atherosclerosis and Immunity: A Perspective, Trends Cardiovasc. Med., 29, 363, 10.1016/j.tcm.2018.09.017 · DOI
  25. Pirillo, 2013, LOX-1, OxLDL, and Atherosclerosis, Mediators Inflamm., 2013, 152786, 10.1155/2013/152786 · DOI · Paper page
  26. Nickel, 2009, OxLDL Uptake by Dendritic Cells Induces Upregulation of Scavenger-Receptors, Maturation and Differentiation, Atherosclerosis, 205, 442, 10.1016/j.atherosclerosis.2009.01.002 · DOI
  27. Linton, M.F., Yancey, P.G., Davies, S.S., Jerome, W.G., Linton, E.F., Song, W.L., Doran, A.C., and Vickers, K.C. (2019). The Role of Lipids and Lipoproteins in Atherosclerosis. Endotext Internet, Available online: https://www.ncbi.nlm.nih.gov/books/NBK343489/.
  28. Millette, 2006, Platelet-Derived Growth Factor-BB Transactivates the Fibroblast Growth Factor Receptor to Induce Proliferation in Human Smooth Muscle Cells, Trends Cardiovasc. Med., 16, 25, 10.1016/j.tcm.2005.11.003 · DOI
  29. Nakahara, 2017, Coronary Artery Calcification: From Mechanism to Molecular Imaging, JACC Cardiovasc. Imaging, 10, 582, 10.1016/j.jcmg.2017.03.005 · DOI · Paper page
  30. Clemente, 2020, Vascular and Valvular Calcification Biomarkers, Adv. Clin. Chem., 95, 73, 10.1016/bs.acc.2019.08.002 · DOI
  31. Lippi, 2011, Arterial Thrombus Formation in Cardiovascular Disease, Nat. Rev. Cardiol., 8, 502, 10.1038/nrcardio.2011.91 · DOI · Paper page
  32. Ouweneel, 2016, Lipoproteins as Modulators of Atherothrombosis: From Endothelial Function to Primary and Secondary Coagulation, Vascul. Pharmacol., 82, 1, 10.1016/j.vph.2015.10.009 · DOI
  33. Mućka, S., Miodońska, M., Jakubiak, G.K., Starzak, M., Cieślar, G., and Stanek, A. (2022). Endothelial Function Assessment by Flow-Mediated Dilation Method: A Valuable Tool in the Evaluation of the Cardiovascular System. Int. J. Environ. Res. Public Health, 19. · DOI
  34. Papagiouvanni, 2022, Endothelial and microvascular function in liver cirrhosis: An old concept that needs re-evaluation?, Ann. Gastroenterol., 35, 471
  35. Goldberg, 2011, Triglycerides and Heart Disease: Still a Hypothesis?, Arterioscler. Thromb. Vasc. Biol., 31, 1716, 10.1161/ATVBAHA.111.226100 · DOI · Paper page
  36. Płaczkowska, S., Sołkiewicz, K., Bednarz-Misa, I., and Kratz, E.M. (2022). Atherogenic Plasma Index or Non-High-Density Lipoproteins as Markers Best Reflecting Age-Related High Concentrations of Small Dense Low-Density Lipoproteins. Int. J. Mol. Sci., 23. · DOI
  37. Guo, 2020, The Sensibility of the New Blood Lipid Indicator Atherogenic Index of Plasma (AIP) in Menopausal Women with Coronary Artery Disease, Lipids Health Dis., 19, 1, 10.1186/s12944-020-01208-8 · doi:10.1186/s12944-020-01208-8
  38. Tian, 2019, Targeting LOX-1 in atherosclerosis and vasculopathy: Current knowledge and future perspectives, Ann. N. Y. Acad. Sci., 1443, 34, 10.1111/nyas.13984 · DOI
  39. Varghese, 2021, Pathological Crosstalk Between Oxidized LDL and ER Stress in Human Diseases: A Comprehensive Review, Front. Cell Dev. Biol., 9, 674103, 10.3389/fcell.2021.674103 · DOI
  40. Zingg, J.M., Vlad, A., and Ricciarelli, R. (2021). Oxidized LDLs as Signaling Molecules. Antioxidants, 10. · DOI
  41. Gao, 2017, Association Between Circulating Oxidized LDL and Atherosclerotic Cardiovascular Disease: A Meta-analysis of Observational Studies, Can. J. Cardiol., 33, 1624, 10.1016/j.cjca.2017.07.015 · DOI
  42. Gao, 2018, Circulating Oxidized Low-Density Lipoprotein Levels Independently Predict 10-Year Progression of Subclinical Carotid Atherosclerosis: A Community-Based Cohort Study, J. Atheroscler Thromb., 25, 1032, 10.5551/jat.43299 · DOI
  43. Jamialahmadi, 2022, The Effects of Statin Therapy on Oxidized LDL and Its Antibodies: A Systematic Review and Meta-Analysis, Oxid. Med. Cell Longev., 2022, 7850659, 10.1155/2022/7850659 · DOI
  44. Banerjee, 2019, Beyond LDL-c: The importance of serum oxidized LDL in predicting risk for type 2 diabetes in the middle-aged Asian Indians, Diabetes Metab. Syndr., 13, 206, 10.1016/j.dsx.2018.08.036 · DOI
  45. Nishi, 2002, Oxidized LDL in carotid plaques and plasma associates with plaque instability, Arterioscler. Thromb. Vasc. Biol., 22, 1649, 10.1161/01.ATV.0000033829.14012.18 · DOI · Paper page
  46. Hartley, 2019, Oxidized LDL and anti-oxidized LDL antibodies in atherosclerosis—Novel insights and future directions in diagnosis and therapy, Trends Cardiovasc. Med., 29, 22, 10.1016/j.tcm.2018.05.010 · DOI · Paper page
  47. Jakubiak, G.K., Cieślar, G., and Stanek, A. (2022). Nitrotyrosine, Nitrated Lipoproteins, and Cardio-vascular Dysfunction in Patients with Type 2 Diabetes: What Do We Know and What Remains to Be Explained?. Antioxidants, 11. · DOI
  48. Lee, C.-K., Liao, C.-W., Meng, S.-W., Wu, W.-K., Chiang, J.-Y., and Wu, M.-S. (2021). Lipids and Lipoproteins in Health and Disease: Focus on Targeting Atherosclerosis. Biomedicines, 9. · DOI
  49. Ali, 2012, Cardiovascular Disease Risk Reduction by Raising HDL Cholesterol–Current Therapies and Future Opportunities, Br. J. Pharmacol., 167, 1177, 10.1111/j.1476-5381.2012.02081.x · DOI · Paper page
  50. Brea, 2019, Non-HDL Cholesterol as a Therapeutic Goal, Clin. Investig. Arterioscler., 31, 28
  51. Rana, 2012, The Role of Non-HDL Cholesterol in Risk Stratification for Coronary Artery Disease, Curr. Atheroscler. Rep., 14, 130, 10.1007/s11883-011-0224-x · DOI
  52. Brunner, 2019, Application of Non-HDL Cholesterol for Population-Based Cardiovascular Risk Stratification: Results from the Multinational Cardiovascular Risk Consortium, Lancet, 394, 2173, 10.1016/S0140-6736(19)32519-X · DOI · Paper page
  53. Wang, 2021, Non–High-Density Lipoprotein Cholesterol Predicts Adverse Outcomes in Acute Ischemic Stroke, Stroke, 52, 2035, 10.1161/STROKEAHA.120.030783 · DOI
  54. Li, 2011, Serum Non-High-Density Lipoprotein Cholesterol Concentration and Risk of Death from Cardiovascular Diseases among US Adults with Diagnosed Diabetes: The Third National Health and Nutrition Examination Survey Linked Mortality Study, Cardiovasc. Diabetol., 10, 1, 10.1186/1475-2840-10-46 · DOI
  55. Liu, 2017, Meta-Analysis of Serum Non-High-Density Lipoprotein Cholesterol and Risk of Coronary Heart Disease in the General Population, Clin. Chim. Acta, 471, 23, 10.1016/j.cca.2017.05.006 · DOI
  56. Duncan, 2019, Trajectories of Blood Lipid Concentrations over the Adult Life Course and Risk of Cardiovascular Disease and All-cause Mortality: Observations from the Framingham Study over 35 Years, J. Am. Heart Assoc., 8, e011433, 10.1161/JAHA.118.011433 · DOI · Paper page
  57. Peterson, 2015, Hyperlipidemia in Early Adulthood Increases Long-Term Risk of Coronary Heart Disease, Circulation, 131, 451, 10.1161/CIRCULATIONAHA.114.012477 · DOI · Paper page
  58. Liao, 2017, Prognostic Value of Non-High-Density Lipoprotein Cholesterol for Mortality in Patients with Coronary Heart Disease: A Systematic Reviewemnant cholesterol and myocardial infarction in normal weight, overweight, and obese individuals from the Copenhagen General Population Study and Meta-Analysis, Int. J. Cardiol., 227, 950, 10.1016/j.ijcard.2016.10.106 · DOI
  59. We, 2019, Associations of non-high-density are effective lipoprotein cholesterol, triglycerides and the total cholesterol/HDL-c ratio with arterial stiffness independent of low-density lipoprotein cholesterol in a Chinese population, Hypertens. Res., 42, 1223, 10.1038/s41440-019-0251-5 · DOI
  60. Parhofer, 2022, New targets for treating hypertriglyceridemia, Curr. Opin. Endocrinol. Diabetes Obes., 29, 106, 10.1097/MED.0000000000000714 · DOI
  61. Carr, 2019, Non-HDL-cholesterol and apolipoprotein B compared with LDL-cholesterol in atherosclerotic cardiovascular disease risk assessment, Pathology, 51, 148, 10.1016/j.pathol.2018.11.006 · DOI · Paper page
  62. Hoogeveen, 2021, Residual Cardiovascular Risk at Low LDL: Remnants, Lipoprotein(a), and Inflammation, Clin. Chem., 67, 143, 10.1093/clinchem/hvaa252 · DOI · Paper page
  63. 2021, Triglyceride-rich lipoproteins and atherosclerotic cardiovascular disease risk: Current status and treatments, Curr. Opin. Endocrinol. Diabetes Obes., 28, 85, 10.1097/MED.0000000000000619 · DOI
  64. Barter, 2006, Apo B versus Cholesterol in Estimating Cardiovascular Risk and in Guiding Therapy: Report of the Thirty-person/Ten-country Panel, J. Intern. Med., 259, 247, 10.1111/j.1365-2796.2006.01616.x · DOI · Paper page
  65. Robinson, 2012, Meta-Analysis of Comparison of Effectiveness of Lowering Apolipoprotein B versus Low-Density Lipoprotein Cholesterol and Nonhigh-Density Lipoprotein Cholesterol for Cardiovascular Risk Reduction in Randomized Trials, Am. J. Cardiol., 110, 1468, 10.1016/j.amjcard.2012.07.007 · DOI
  66. Hodkinson, 2022, Comparative Effectiveness of Statins on Non-High Density Lipoprotein Cholesterol in People with Diabetes and at Risk of Cardiovascular Disease: Systematic Review and Network Meta-Analysis, BMJ, 376, e067731-74
  67. Pencina, 2019, Trajectories of Non–HDL Cholesterol across Midlife: Implications for Cardiovascular Prevention, J. Am. Coll. Cardiol., 74, 70, 10.1016/j.jacc.2019.04.047 · DOI · Paper page
  68. Armstrong, 2021, Association of Non-High-Density Lipoprotein Cholesterol Measured in Adolescence, Young Adulthood, and Mid-Adulthood With Coronary Artery Calcification Measured in Mid-Adulthood, JAMA Cardiol., 6, 661, 10.1001/jamacardio.2020.7238 · DOI · Paper page
  69. Castelli, 1983, Summary Estimates of Cholesterol Used to Predict Coronary Heart Disease, Circulation, 67, 730, 10.1161/01.CIR.67.4.730 · DOI · Paper page
  70. Pallardo, 2009, Lipoprotein Ratios: Physiological Significance and Clinical Usefulness in Cardiovascular Prevention, Vasc. Health Risk Manag., 5, 757
  71. Albrektsen, 2017, Risk of incident myocardial infarction by gender: Interactions with serum lipids, blood pressure and smoking. The Tromsø Study 1979–2012, Atherosclerosis, 261, 52, 10.1016/j.atherosclerosis.2017.04.009 · DOI
  72. Langer, 2003, Sex and time differences in the associations of non-high-density lipoprotein cholesterol versus other lipid and lipoprotein factors in the prediction of cardiovascular death (The Rancho Bernardo Study), Am. J. Cardiol., 91, 1311, 10.1016/S0002-9149(03)00319-9 · DOI
  73. Kouvari, M., Panagiotakos, D.B., Chrysohoou, C., Georgousopoulou, E.N., Tousoulis, D., and Pitsavos, C. (2020). Sex-Related Differences of the Effect of Lipoproteins and Apolipoproteins on 10-Year Cardiovascular Disease Risk; Insights from the ATTICA Study (2002–2012). Molecules, 25. · DOI
  74. Vigna, 2022, Insulin Resistance and Cardiometabolic Indexes: Comparison of Concordance in Working-Age Subjects with Overweight and Obesity, Endocrine, 77, 1, 10.1007/s12020-022-03087-8 · DOI
  75. Lemieux, 2001, Total Cholesterol/HDL Cholesterol Ratio vrequiring extensive reorganization and re-writings LDL Cholesterol/HDL Cholesterol Ratio as Indices of Ischemic Heart Disease Risk in Men: The Quebec Cardiovascular Study, Arch. Intern. Med., 161, 2685, 10.1001/archinte.161.22.2685 · DOI · Paper page
  76. Bhardwaj, 2013, Atherogenic Index of Plasma, Castelli Risk Index and Atherogenic Coefficient-New Parameters in Assessing Cardiovascular Risk, Int. J. Pharm. Biol. Sci., 3, 359
  77. Nair, 2009, Association of Total Cholesterol/High-density Lipoprotein Cholesterol Ratio with Proximal Coronary Atherosclerosis Detected by Multislice Computed Tomography, Prev. Cardiol., 12, 19, 10.1111/j.1751-7141.2008.00011.x · DOI
  78. Liu, 2021, Association of Triglyceride-Rich Lipoprotein-Cholesterol with Recurrent Cardiovascular Events in Statin-Treated Patients According to Different Inflammatory Status, Atherosclerosis, 330, 29, 10.1016/j.atherosclerosis.2021.06.907 · DOI
  79. Li, 2021, Atherogenic index of plasma as predictors for metabolic syndrome, hy-pertension and diabetes mellitus in Taiwan citizens: A 9-year longitudinal study, Sci. Rep., 11, 9900, 10.1038/s41598-021-89307-z · DOI · Paper page
  80. Khakurel, 2018, Atherogenic Index of Plasma in Postmenopausal Women, J. Nepal. Health Res. Counc., 16, 175, 10.33314/jnhrc.v16i2.1570 · doi:10.33314/jnhrc.v16i2.1570
  81. Cai, 2017, The atherogenic index of plasma is a strong and independent predictor for coronary artery dis-ease in the Chinese Han population, Medicine (Baltimore), 96, e8058, 10.1097/MD.0000000000008058 · DOI · Paper page
  82. Hartopo, 2016, Low Plasma Atherogenic Index Associated with Poor Prognosis in Hospitalized Patients with Acute Myocardial Infarction, Acta Medica Indones., 48, 106
  83. Shin, H.R., Song, S., Cho, J.A., and Ly, S.Y. (2022). Atherogenic Index of Plasma and Its Association with Risk Factors of Coronary Artery Disease and Nutrient Intake in Korean Adult Men: The 2013–2014 KNHANES. Nutrients, 14. · DOI
  84. Li, 2018, Atherogenic Index in Type 2 Diabetes and Its Relationship with Chronic Microvascular Complications, Int. J. Endocrinol., 2018, 1765835, 10.1155/2018/1765835 · DOI
  85. Qin, 2020, The atherogenic index of plasma plays an important role in predicting the prognosis of type 2 diabetic subjects undergoing percutaneous coronary intervention: Results from an observational cohort study in China, Cardiovasc. Diabetol., 19, 23, 10.1186/s12933-020-0989-8 · DOI
  86. Zhou, 2021, The Atherogenic Index of Plasma: A Powerful and Reliable Predictor for Coronary Artery Disease in Patients with Type 2 Diabetes, Angiology, 72, 934, 10.1177/00033197211012129 · DOI
  87. Mangalesh, 2022, Atherogenic index of plasma predicts coronary artery disease severity and major adverse cardiac events in absence of conventional risk factors, Coron. Artery Dis., 33, 523, 10.1097/MCA.0000000000001166 · DOI
  88. Shui, 2022, Association of Atherogenic Index of Plasma With Angiographic Progression in Patients With Suspected Coronary Artery Disease, Angiology, 1, 33197221080911
  89. Zhan, Y., Xu, T., and Tan, X. (2016). Two parameters reflect lipid-driven inflammatory state in acute coronary syndrome: Atherogenic index of plasma, neutrophil-lymphocyte ratio. BMC Cardiovasc. Disord., 16. · DOI
  90. McLaughlin, 2005, Is There a Simple Way to Identify Insulin-Resistant Individuals at Increased Risk of Cardiovascular Disease?, Am. J. Cardiol., 96, 399, 10.1016/j.amjcard.2005.03.085 · DOI · Paper page
  91. Sirtori, 2001, Cardiovascular status of carriers of the apolipoprotein A-I(Milano) mutant: The Limone sul Garda study, Circulation, 103, 1949, 10.1161/01.CIR.103.15.1949 · DOI · Paper page
  92. Bielicki, 2002, Apolipoprotein A-I(Milano) and apolipoprotein A-I(Paris) exhibit an antioxidant activity distinct from that of wild-type apolipoprotein A-I, Biochemistry, 41, 2089, 10.1021/bi011716p · DOI · Paper page
  93. Zhang, 2020, Trends in LDL and Non-HDL Levels with Age, Aging Dis., 11, 1046, 10.14336/AD.2019.1025 · DOI

Metadata

Authors
Gaggini, M., Gorini, F., & Vassalle, C.
Venue
International Journal of Molecular Sciences
Publisher
MDPI AG
Published
2022-12-21
Volume
24
Issue
1
Pages
75
ISSN
1422-0067
Cited by
163
References
28
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.